Using A.I. to Advance Understanding of Long COVID
Rajarshi Banerjee, Ph.D., Co-Founder and CEO of Perspectum, a digital medical technology and diagnostics company, talks about why A.I. is playing a growing role in medical imaging’s fight against long COVID, and how multi-organ scanning is being used to help physicians see the impact of long COVID. Perspectum’s CoverScan technology has been approved by the UK’s NHS for use in diagnosing long COVID and it recently received FDA clearance in the U.S. for multi-organ scanning.
Rajarshi Banerjee, Ph.D. has served as Chief Executive Officer and a member of the board of directors for Perspectum since November 2012. Prior to co-founding Perspectum in 2012, Dr. Banerjee was a research fellow at the University of Oxford and developed the magnetic resonance imaging techniques for rapid non-invasive liver assessment and commercialized the method as LiverMultiScan, which has received 510(k) clearance from the FDA and is used in over 500 sites. Dr. Banerjee continues to work as a consultant physician with the Oxford University Hospitals NHS Foundation Trust, with research into the phenotyping of liver disease at an individual and population level in adults and children.
Dr. Banerjee has many years of experience in running clinical trials and working in multidisciplinary scientific teams to develop applications for cutting-edge imaging technology and is a keen advocate of smart trial design. Dr. Banerjee received a BM. BCh. in Medicine and a Ph.D. in Cardiovascular Health from the University of Oxford, as well as a MSc. in Public Health from the London School of Hygiene and Tropical Medicine.
